纵览阿司匹林发展历史

doi:10.3969/j.issn.1007-9572.2016.26.001

摘要/Abstract

摘要： 为了提供对阿司匹林最新的全面认识，本文回顾了阿司匹林自发现以来的重大研究，并简述了其在各领域的新发展。指出阿司匹林作为百年老药，不仅在心血管领域有着不可动摇的基石地位，还在其他方面发挥新的作用，给人类带来更多益处。

Abstract: This paper reviews key studies and novel developments regarding aspirin in all fields to enhance our understanding of this drug.As a century-old medicine,aspirin plays a major role in cardiovascular and other fields.Thus,this drug provides beneficial outcomes for affected individuals.

中图分类号:

971.1

汪芳. 纵览阿司匹林发展历史[J]. 中国全科医学, 2016, 19(26): 3129-3135.

WANG Fang. Overview on the History of Aspirin[J]. Chinese General Practice, 2016, 19(26): 3129-3135.

参考文献

［1］BIBBINS-DOMINGO K，U.S.Preventive Services Task Force.Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer：U.S.Preventive Services Task Force Recommendation Statement［J］.Ann Intern Med，2016，164（12）：836-845. ［2］FUSTER V，SWEENY J M.Aspirin：a historical and contemporary therapeutic overview［J］.Circulation，2011，123（7）：768-778. ［3］WICK J Y.Aspirin：a history，a love story［J］.Consult Pharm，2012，27（5）：322-329. ［4］SNEADER W.The discovery of aspirin:a reappraisal［J］.BMJ，2000，321（7276）：1591-1594. ［5］SINGER R.Acetylsalicylic acid，a probable cause for secondary post-tonsillectomy hemorrhage［J］.Arch Otolaryngol，1945，42（1）：19-20. ［6］MINER J，HOFFHINES A.The discovery of aspirin’s antithrombotic effects［J］.Tex Heart Inst J，2007，34（2）：179-186. ［7］ELWOOD P C，COCHRANE A L，BURR M L，et al.A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction［J］.Br Med J，1974，1（5905）：436-440. ［8］FIELDS W S，LEMAK N A，FRANKOWSKI R F，et al.Controlled trial of aspirin incerebral ischemia［J］.Stroke，1977，8（3）：301-314. ［9］The European Stroke Prevention Study （ESPS）.Principal endpoints.The ESPS Group ［J］.Lancet，1987，2（8572）：1351-1354. ［10］DIENER H C，CUNHA L，FORBES C，et al.European Stroke Prevention Study.2.Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke［J］.J Neurol Sci，1996，143（1/2）：1-13. ［11］Swedish Aspirin Low-Dose Trial（SALT） of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.The SALT Collaborative Group［J］.Lancet，1991，338（8779）：1345-1349. ［12］The International Stroke Trial（IST）:a randomised trial of aspirin，subcutaneous heparin，both，or neither among 19435 patients with acute ischaemic stroke.International Stroke Trial Collaborative Group［J］.Lancet，1997，349（9065）：1569-1581. ［13］CAST：randomised placebo-controlled trial of early aspirin use in 20，000 patients with acute ischaemic stroke.CAST （Chinese Acute Stroke Trial）Collaborative Group［J］.Lancet，1997，349（9066）：1641-1649. ［14］RIDKER P M，COOK N R，LEE I M，et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women［J］.N Engl J Med，2005，352（13）：1293-1304. ［15］Antithrombotic Trialists’ （ATT） Collaboration,BAIGENT C，BLACKWELL L,et al.Aspirin in the primary and secondary prevention of vascular disease：collaborative meta-analysis of individual participant data from randomised trials［J］.Lancet，2009，373（9678）：1849-1860. ［16］KERNAN W N，OVBIAGELE B，BLACK H R，et al.Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline for healthcare professionals from the American Heart Association/American Stroke Association［J］.Stroke，2014，45（7）：2160-2236. ［17］中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014［J］.中华神经科杂志，2015，48（4）：258-273. ［18］中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国脑血管病一级预防指南2015［J］.中华神经科杂志，2015，48（8）：629-643. ［19］MESCHIA J F，BUSHNELL C，BODEN-ALBALA B，et al.Guidelines for the primary prevention of stroke：a statement for healthcare professionals from the American Heart Association/American Stroke Association［J］.Stroke，2014，45（12）：3754-3832. ［20］Aspirin in coronary heart disease.The Coronary Drug Project Research Group［J］.Circulation，1980，62（6 Pt 2）：V59-62. ［21］Randomised trial of intravenous streptokinase，oral aspirin，both，or neither among 17，187 cases of suspected acute myocardial infarction：ISIS-2.ISIS-2（Second International Study of Infarct Survival） Collaborative Group ［J］.Lancet，1988，2（8607）：349-360. ［22］AMSTERDAM E A，WENGER N K，BRINDIS R G，et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines［J］.Circulation，2014，130（25）：2354-2394. ［23］中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南［J］.中华心血管病杂志，2015，43（5）：380-393. ［24］PETO R，GRAY R，COLLINS R，et al.Randomised trial of prophylactic daily aspirin in British male doctors［J］.Br Med J （Clin Res Ed），1988，296（6618）：313-316. ［25］Final report on the aspirin component of the ongoing Physicians’ Health Study.Steering Committee of the Physicians’ Health Study Research Group［J］.N Engl J Med，1989，321（3）：129-135. ［26］Thrombosis prevention trial：randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.The Medical Research Council’s General Practice Research Framework［J］.Lancet，1998，351（9098）：233-241. ［27］HANSSON L，ZANCHETTI A，CARRUTHERS S G，et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment （HOT） randomised trial.HOT Study Group［J］.Lancet，1998，351（9118）：1755-1762. ［28］DE GAETANO G,Collaborative Group of the Primary Prevention Project.Low-dose aspirin and vitamin E in people at cardiovascular risk：a randomised trial in general practice.Collaborative Group of the Primary Prevention Project［J］.Lancet，2001，357（9250）：89-95. ［29］IKEDA Y，SHIMADA K，TERAMOTO T，et al.Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors:a randomized clinical trial［J］.JAMA，2014，312（23）：2510-2520. ［30］中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心血管病预防指南［J］.中华心血管病杂志，2011，39（1）：3-21. Chinese Society of Cardiology of Chinese Medical Association,Editorial Board of Chinese Journal of Cardiology.Chinese guidelines for prevention of cardiovascular diseases［J］.Chinese Journal of Cardiology，2011，39（1）：3-21. ［31］HALVORSEN S，ANDREOTTI F，TEN BERG J M，et al.Aspirin therapy in primary cardiovascular disease prevention：a position paper of the European Society of Cardiology working group on thrombosis［J］.J Am Coll Cardiol，2014，64（3）：319-327. ［32］中华医学会心血管病学分会，中华心血管病杂志编辑委员会.抗血小板治疗中国专家共识［J］.中华心血管病杂志，2013，41（3）：183-194. ［33］CHUBAK J，WHITLOCK E P，WILLIAMS S B，et al.Aspirin for the prevention of cancer incidence and mortality：systematic evidence reviews for the U.S.Preventive Services Task Force［J］.Ann Intern Med，2016,164（12）:814-825. ［34］ROTHWELL P M，WILSON M，ELWIN C E，et al.Long-term effect of aspirin on colorectal cancer incidence and mortality：20-year follow-up of five randomised trials［J］.Lancet，2010，376（9754）：1741-1750. ［35］BURN J，GERDES A M，MACRAE F，et al.Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer：an analysis from the CAPP2 randomised controlled trial［J］.Lancet，2011，378（9809）：2081-2087. ［36］LI P，WU H，ZHANG H，et al.Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival：a meta-analysis［J］.Gut，2015，64（9）：1419-1425. ［37］CAO Y，NISHIHARA R，WU K，et al.Population-wide impact of long-term use of aspirin and the risk for cancer［J］.JAMA Oncol，2016,2（6）:762-769. ［38］KIM Y I，KIM S Y，KIM J H，et al.Long-term low-dose aspirin use reduces gastric cancer incidence：a nationwide cohort study［J］.Cancer Res Treat，2016，48（2）：798-805. ［39］WANG Y，SHEN C，GE J，et al.Regular aspirin use and stomach cancer risk in China［J］.Eur J Surg Oncol，2015，41（6）：801-804. ［40］CHOI J，GHOZ H M，PEERAPHATDIT T，et al.Risk factors for cholangiocarcinoma：aspirin-use and the risk of cholangiocarcinoma［J］.Hepatology，2016. ［41］MACFARLANE T V，MURCHIE P，WATSON M C.Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer［J］.Cancer Epidemiol，2015，39（6）：1015-1022. ［42］DI MASO M，BOSETTI C，LA VECCHIA C，et al.Regular aspirin use and nasopharyngeal cancer risk:a case-control study in Italy［J］.Cancer Epidemiol，2015，39（4）：545-547. ［43］OH S W，MYUNG S K，PARK J Y，et al.Aspirin use and risk for lung cancer：a meta-analysis［J］.Ann Oncol，2011，22（11）：2456-2465. ［44］LAPI F，LEVI M，SIMONETTI M，et al.Risk of prostate cancer in low-dose aspirin users：a retrospective cohort study［J］.Int J Cancer，2016，139（1）：205-211. ［45］PASTORE A，PALLESCHI G，FUSCHI A，et al.Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? Aretrospective study on a cohort of patients undergoing transurethral bladder resection［J］.BMC Cancer，2015，15：120. ［46］BARDIA A，KEENAN T E，EBBERT J O，et al.Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women［J］.Mayo Clin Proc，2016，91（1）：71-80. ［47］NEILL A S，NAGLE C M，PROTANI M M，et al.Aspirin，nonsteroidal anti-inflammatory drugs，paracetamol and risk of endometrial cancer:a case-control study，systematic review and meta-analysis［J］.Int J Cancer，2013，132（5）：1146-1155. ［48］TRABERT B，NESS R B，LO-CIGANIC W H，et al.Aspirin，nonaspirin nonsteroidal anti-inflammatory drug，and cetaminophen use and risk of invasive epithelial ovarian cancer:a pooled analysis in the Ovarian Cancer Association Consortium［J］.J Natl Cancer Inst，2014，106（2）：djt431. ［49］LEFEVRE M L,U.S.Preventive Services Task Force.Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia：U.S.Preventive Services Task Force recommendation statement［J］.Ann Intern Med，2014，161（11）：819-826. ［50］XU T T，ZHOU F，DENG C Y，et al.Low-dose aspirin for preventing preeclampsia and its complications:a meta-analysis［J］.J Clin Hypertens （Greenwich），2015，17（7）：567-573. ［51］KERN S，SKOOG I，OSTLING S，et al.Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk?A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women［J］.BMJ Open，2012，2（5）.pii:e001288. ［52］BERK M，DEAN O，DREXHAGE H，et al.Aspirin:a review of its neurobiological properties and therapeutic potential for mental illness［J］.BMC Med，2013，11：74. ［53］LAAN W，GROBBEE D E，SELTEN J P，et al.Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders:results from a randomized，double-blind，placebo-controlled trial［J］.J Clin Psychiatry，2010，71（5）：520-527. ［54］JIANG Z G，FELDBRGGE L，TAPPER E B，et al.Aspirin use is associated with lower indices of liver fibrosis among adults in the United States［J］.Aliment Pharmacol Ther，2016，43（6）：734-743. ［55］GUILLEM-LLOBAT P，DOVIZIO M，ALBERTI S，et al.Platelets，cyclooxygenases，and colon cancer［J］.Semin Oncol，2014，41（3）：385-396. ［56］GOUBRAN H A，STAKIW J，RADOSEVIC M，et al.Platelets effects on tumor growth［J］.Semin Oncol，2014，41（3）：359-369. ［57］SCHRR K.Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer［J］.Best Pract Res Clin Gastroenterol，2011，25（4/5）：473-484. ［58］VERHEUGT F W，BOLTE A C.The role of aspirin in women’s health［J］.Int J Womens Health，2011，3：151-166. ［59］DE BERARDIS G，SACCO M，EVANGELISTA V，et al.Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes （ACCEPT-D）：design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins［J］.Trials，2007，8：21. ［60］ASPREE Investigator Group.Study design of ASPirin in Reducing Events in the Elderly （ASPREE）:a randomized，controlled trial［J］.Contemp Clin Trials，2013，36（2）：555-564. ［61］LOWTHIAN J A，BRITT C J，RANCE G，et al.Slowing the progression of age-related hearing loss:rationale and study design of the ASPIRIN in HEARING，retinal vessels imaging and neurocognition in older generations （ASPREE-HEARING） trial［J］.Contemp Clin Trials，2016，46：60-66. ［62］BARKER A L，MCNEIL J J，SEEMAN E，et al.A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people:protocol for the ASPREE-Fracture substudy［J］.Inj Prev，2016，22（4）:297-301. ［63］MYLES P S，SMITH J，KNIGHT J，et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery （ATACAS） Trial:rationale and design［J］.Am Heart J，2008，155（2）：224-230. ［64］ALI R，TOH H C，CHIA W K,et al.The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer——the ASCOLT study：study protocol for a randomized controlled trial［J］.Trials，2011，12：261. ［65］HULL M A，SANDELL A C，MONTGOMERY A A，et al.A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme （The seAFOod Polyp Prevention Trial）：study protocol for a randomized controlled trial［J］.Trials，2013，14：237. ［66］LIN D.In Vivo Molecular Effects of Aspirin on Prostate Tissue［OL］.（2016-05-24）［2016-07-01］.https://clinicaltrials.gov/ct2/show/NCT00234299?term=NCT00234299&rank=1. ［67］AIDS Clinical Trials Group.Modulation of Immune Activation by Aspirin［OL］.（2016-05-27）［2016-07-01］.https://clinicaltrials.gov/ct2/show/NCT02155985?term=NCT02155985&rank=1. ［68］WELLER C D，BARKER A，DARBY I，et al.Aspirin in venous leg ulcer study （ASPiVLU）:study protocol for a randomised controlled trial［J］.Trials，2016，17（1）：192.

[1]	项天乐, 周娜, 李芳, 曹梅娟. 儿童24 h活动行为测评方法研究进展[J]. 中国全科医学, 2026, 29(06): 760-766.
[2]	王立娜, 雷警输, 李奎宝, 王睿颖, 李新苗, 王芳芳, 郭晓荣, 牛瑞浩, 赵伟, 周芳芳, 赵京晶, 李忠佑. 急性心肌梗死患者炎症反应研究进展[J]. 中国全科医学, 2026, 29(06): 790-801.
[3]	史佳琦, 王玉欣, 罗佳妮, 姜琪, 吴善玉, 金头峰. 胃肠道癌症患者症状群影响因素的范围综述[J]. 中国全科医学, 2026, 29(05): 668-675.
[4]	田紫薇, 杨支兰, 赵慧敏, 翟艳萍, 李鸿雁, 杜淼, 晋源媛, 宋泽雨. 膝骨关节炎患者衰弱研究的范围综述[J]. 中国全科医学, 2026, 29(05): 676-680.
[5]	曹新阳, 汪洋, 金花, 于德华, 杨辉, 刘晓云, 许岩丽. 全科医学科研能力发展的影响因素：一项范围综述[J]. 中国全科医学, 2026, 29(04): 444-456.
[6]	王艺衡, 许晓明, 夏云龙, 夏林莺, 韩雪, 郭永珍, 刘泉池, 闫文俊. 射血分数保留的心力衰竭药物治疗进展[J]. 中国全科医学, 2026, 29(03): 403-408.
[7]	刘燕, 袁艳玲, 令榕, 王兰云, 孙丽. 远程医疗在冠心病患者心脏康复中应用的范围综述[J]. 中国全科医学, 2025, 28(36): 4640-4647.
[8]	王怡, 程金湘, 赵显超, 任佳封, 张丽萍, 董孟龙, 林志烽, 宿长军. 药物相关的快速眼动睡眠行为障碍研究新进展[J]. 中国全科医学, 2025, 28(35): 4511-4516.
[9]	李明月, 汤皓晴, 郑汇娴, 张笑天, 刘晓云. 基本卫生保健质量概念内涵研究的系统综述[J]. 中国全科医学, 2025, 28(34): 4300-4310.
[10]	王梦奇, 梁墨瑄, 李泽远, 郭玉婷, 程景民. 间歇性禁食对2型糖尿病患者应用效果的范围综述[J]. 中国全科医学, 2025, 28(33): 4234-4240.
[11]	高佳新, 周蕊寒, 王芳芳, 庞日朝, 张安仁. 饮食限制对机体免疫功能调节作用的研究进展[J]. 中国全科医学, 2025, 28(32): 4102-4109.
[12]	张曦, 管成果, 王婧, 许丁昕, 张博. 痴呆症患者预立医疗照护计划干预策略的研究新进展[J]. 中国全科医学, 2025, 28(32): 4109-4116.
[13]	王婷婷, 唐勇, 张文轲, 李志刚. 高尿酸血症运动干预的研究进展[J]. 中国全科医学, 2025, 28(30): 3841-3846.
[14]	农景堂, 杨成敏, 莫圣龙, 陆志成, 唐丽娜, 简崇东, 商敬伟. 脑梗死预后相关生物标志物的研究新进展：机制与临床应用[J]. 中国全科医学, 2025, 28(29): 3711-3720.
[15]	李仪丙, 贾鸿博, 樊小农, 赵文君, 刘巍, 葛文逸, 李宋姣, 雷康辰, 张梦龙, 张薇薇, 陈阳, 李礼. 卒中后吞咽障碍预后影响因素的综合评估：一项伞形综述[J]. 中国全科医学, 2025, 28(29): 3631-3637.